July 03, 2025 Kigali, Rwanda and San Francisco, USA

This week's announcement of a landmark Partnership Agreement with Bioeq AG (Announcement) was due in no small part to the tireless efforts of Vince Anicetti, Bio Usawa Board member and Chair of the Manufacturing Advisory Board.

"Our new strategic partnership opens the door to providing effective, affordable high-quality monoclonal antibodies to patients in Sub-Saharan Africa suffering from potentially blinding eye disease. Bio Usawa is indeed fortunate to have forged this relationship, as we together take a giant step forward to democratize healthcare in Africa and beyond." - Vince Anicetti, MS

About Bio Usawa, Inc. (BUI)

Bio Usawa has a singular mission: to manufacture and commercialize high-quality, effective and affordable biosimilars for patients in Africa. We are applying our 100+ years of combined experience in the industry in partnership with governments, agencies, educators and health professionals to make transformative biomedicines in Africa, by Africans, for Africans and beyond. 

Click here to learn more about our company's recent successes and download our new White Paper on Regulatory Approaches to Biosimilars in Africa.